Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and Stable Disease

Conference Correspondent —October 20, 2018


ESMO 2018

The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is approved as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer who are in complete or partial response to platinum-based chemotherapy. However, for patients with stable disease (SD), the efficacy of maintenance olaparib remains unknown. A recent phase 2 study has shown that, compared with maintenance with platinum-based chemotherapy alone, progression-free survival (PFS) can be significantly prolonged in patients with platinum-sensitive relapsed ovarian cancer who receive olaparib plus platinum-based chemotherapy followed by maintenance olaparib.1 Here, Oza and colleagues performed a retrospective post-hoc analysis of outcomes in patients with SD on scans at the end of chemotherapy and the efficacy of maintenance olaparib versus observation.2

In an open-label, multicenter trial, patients with platinum-sensitive relapsed serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer were randomized to receive platinum-based chemotherapy alone, without maintenance olaparib, or olaparib plus platinum-based chemotherapy followed by maintenance olaparib. The most recent scan from randomization up to 2 weeks after the final dose of carboplatin was used to assess the best objective Response Evaluation Criteria in Solid Tumors 1.1 response at the end of chemotherapy using blinded independent central review.

At the end of chemotherapy, 24 (29.6%) patients in the olaparib + chemotherapy group and 21 (25.9%) patients who received chemotherapy alone had SD as their best response (timing of the scan ranged from 2.10 months before to 0.49 months after the last dose of carboplatin). Median PFS, calculated from the end of chemotherapy, was 8.74 months with maintenance olaparib at a standard dose versus 5.4 months without maintenance olaparib (hazard ratio, 0.50; 95% confidence interval, 0.25-1.00; P = .046). Delayed responses following the end of chemotherapy occurred in 4 patients who received maintenance olaparib (16.7%; 2 complete and 2 partial responses) and 3 patients without maintenance olaparib (14.3%; all partial responses). The number of lines of prior chemotherapy did not appear to be predictive of PFS benefit.

Together, these results suggest that maintenance treatment with the PARP inhibitor olaparib is associated with prolonged PFS compared with observation alone in patients with advanced ovarian cancer with SD following platinum-based therapy. The number of lines of prior chemotherapy did not appear to be predictive of PFS benefit.


  1. Oza AM, et al. Lancet Oncol. 2015;16(1):87-97.
  2. Oza AM, et al. ESMO 2018. Abstract 950P.
Related Articles
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Initial Results from an Expansion Cohort Receiving Mirvetuximab Soravtansine/Pembrolizumab for Platinum-Resistant Ovarian Cancer: Initial Results from FORWARD II
Conference Correspondent
The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cance
Conference Correspondent
Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established.
Last modified: October 20, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
  • Please enter your mailing address.

    Address Line 2
    Zip Code